Sort
3,198 grants matching “mrna vaccine”
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$55,953,346Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Flavivirus and Alphavirus ReVAMPP (FLARE)
$46,715,173Michael S. Diamond · Washington University · U19 · FY2024 · AI
Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP
$44,108,652Sean P. J. Whelan · Washington University · U19 · FY2024 · AI
Machine learning-enabled design of prototype pathogen vaccines and antibodies
$41,075,241Neil King · University Of Washington · U19 · FY2024 · AI
The UCI Vaccines for Pandemic Preparedness Center (VPPC)
$33,116,067Philip Louis Felgner · University Of California-Irvine · U19 · FY2024 · AI
Influenza Vaccine Research and Development
$31,820,000Masaru Kanekiyo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Influenza Vaccine Development
$22,147,857Masaru Kanekiyo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
CoVPN 3008, Multi-Center, Randomized, Efficay Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$21,074,900Myron S Cohen · Family Health International · UM1 · FY2021 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$19,404,520Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
Rho Federal Systems Division, Inc. NIAID DAIT SACCC
$15,843,849Gloria David · Rho Federal Systems Division, Inc. · UM2 · FY2021 · AI
Vaccination for Recovered Inpatients with COVID-19 (VATICO)
$15,147,252Laura McNay · Leidos Biomedical Research, Inc. · N01 · FY2021 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$14,844,618Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
CoVPN 3008 2022-2023
$12,647,369Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
The Development and Evaluation of Pan-Coronavirus Vaccines
$7,990,794Michael S. Diamond · Washington University · P01 · FY2022 · AI
Project 1: Adjuvanted Protein Vaccines for Pandemic Preparedness
$7,511,446Li Liang · University Of California-Irvine · U19 · FY2024 · AI
NIAID VRC NUCLEIC ACID AND LIPID TECHNOLOGY DEVELOPMENT
$7,090,787Victoria Coleman · Leidos Biomedical Research, Inc. · N01 · FY2023 · AI
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$7,007,011Judith S. Currier · University Of California Los Angeles · UM1 · FY2022 · AI
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
$7,000,324Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2021 · AI
COVID Protection After Transplant (CPAT) Multicenter Adaptive Trial
$6,941,821Christine Marie Durand · Johns Hopkins University · U01 · FY2021 · AI
Prototype strategy for vaccines and antibodies to Peribunyaviridae
$6,793,772Sean P. J. Whelan · Washington University · U19 · FY2024 · AI
Project 2 - GMP Manufacturing of mRNA Immunogens
$6,432,773Thomas N Denny · Duke University · U19 · FY2022 · AI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
$6,183,078Barton F Haynes · Duke University · U19 · FY2022 · AI
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of mRNA, Lipid Nanoparticle Based HIV Immunogens
$6,174,301Wendell Beres · Duke University · N01 · FY2023 · AI
RII Track-2 FEC: Membrane Purification Platform for Continuous Biomanufacturing of Viral Vectors and Virus-like Particles in Arkansas and Beyond
$5,999,758Xianghong Qian · University Of Arkansas · · FY2022 · O/D
Vaccine and Treatment Evaluation Units (VTEU)
$5,921,655Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2020 · AI